Literature DB >> 24826053

Th22 cells are associated with hepatocellular carcinoma development and progression.

Shanyu Qin1, Shijia Ma1, Xiaoli Huang1, Donghong Lu1, You Zhou1, Haixing Jiang1.   

Abstract

OBJECTIVE: IL-22-producing CD4(+) T helper cells (Th22 cells) have been identified as major inducers of tissue inflammation and immune responses. Currently, no previous study explored the role of Th22 cells in the pathogenesis of hepatocellular carcinoma (HCC). The study aimed to determine the biological function of Th22 cells and its effector IL-22 in HCC patients.
METHODS: Forty-five HCC patients and 19 healthy controls were recruited and their peripheral blood was collected. The fresh HCC tissues, adjacent HCC tissues and ten normal liver tissues were also collected. Flow cytometry analysis was used to determine the frequencies of circulating Th22 cells and Th17 cells. Serum IL-22 levels were tested by enzyme-linked immunosorbent assay (ELISA). Immunohistochemical staining and real-time polymerase chain reaction (PCR) were used to detect IL-22 protein and mRNA in tissues specimens, respectively.
RESULTS: Circulating Th22 cells, Th17 cells and serum IL-22 levels were significantly elevated in HCC patients compared with those of healthy controls (P<0.001). Th22 cells were showed to be positively correlated with IL-22 in HCC patients (P<0.05), but not in healthy controls. No significant differences were found in HCC patients with HBeAg positivity or negativity in term of Th22 cells and serum IL-22 levels. The expression of IL-22 protein and mRNA was highest in HCC tissues, followed by adjacent HCC tissues and normal liver tissues. Furthermore, Th22 cells, serum IL-22 levels and IL-22 mRNA were elevated at stage III-IV compared with stage I-II of HCC (P<0.05).
CONCLUSIONS: Elevation of circulating Th22 cells and IL-22 may be implicated in the pathogenesis of HCC, and potentially be cellular targets for therapeutic intervention.

Entities:  

Keywords:  IL-22; Th22; hepatocellular carcinoma (HCC)

Year:  2014        PMID: 24826053      PMCID: PMC4000908          DOI: 10.3978/j.issn.1000-9604.2014.02.14

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  27 in total

Review 1.  The tumour microenvironment as a target for chemoprevention.

Authors:  Adriana Albini; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

Review 2.  Signaling pathways in hepatocellular carcinoma.

Authors:  Daniela Sia; Augusto Villanueva
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

3.  Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy.

Authors:  Zhi-Jian Ye; Qiong Zhou; Ming-Li Yuan; Rong-Hui Du; Wei-Bing Yang; Xian-Zhi Xiong; Bo Huang; Huan-Zhong Shi
Journal:  Am J Respir Crit Care Med       Date:  2011-12-28       Impact factor: 21.405

4.  Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis.

Authors:  Lei Zhang; Jian-Min Li; Xin-Guang Liu; Dao-Xin Ma; Nai-Wen Hu; Yong-Gang Li; Wei Li; Yu Hu; Shuang Yu; Xun Qu; Mei-Xiang Yang; A-Lei Feng; Guang-Hui Wang
Journal:  J Clin Immunol       Date:  2011-05-10       Impact factor: 8.317

5.  In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression.

Authors:  Ogyi Park; Hua Wang; Honglei Weng; Lionel Feigenbaum; Hai Li; Shi Yin; Sung Hwan Ki; Seong Ho Yoo; Steven Dooley; Fu-Sheng Wang; Howard A Young; Bin Gao
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

6.  Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer.

Authors:  Tao Liu; Liusheng Peng; Peiwu Yu; Yongliang Zhao; Yun Shi; Xuhu Mao; Weisan Chen; Ping Cheng; Tingting Wang; Na Chen; Jinyu Zhang; Xiaofei Liu; Na Li; Gang Guo; Wende Tong; Yuan Zhuang; Quanming Zou
Journal:  J Clin Immunol       Date:  2012-07-04       Impact factor: 8.317

Review 7.  Biology of interleukin-22.

Authors:  Kerstin Wolk; Ellen Witte; Katrin Witte; Katarzyna Warszawska; Robert Sabat
Journal:  Semin Immunopathol       Date:  2010-02-02       Impact factor: 9.623

8.  IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.

Authors:  Stephan Brand; Florian Beigel; Torsten Olszak; Kathrin Zitzmann; Sören T Eichhorst; Jan-Michel Otte; Helmut Diepolder; Andreas Marquardt; Wolfgang Jagla; Andreas Popp; Stéphane Leclair; Karin Herrmann; Julia Seiderer; Thomas Ochsenkühn; Burkhard Göke; Christoph J Auernhammer; Julia Dambacher
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-04       Impact factor: 4.052

9.  Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling.

Authors:  Stefanie Eyerich; Kilian Eyerich; Davide Pennino; Teresa Carbone; Francesca Nasorri; Sabatino Pallotta; Francesca Cianfarani; Teresa Odorisio; Claudia Traidl-Hoffmann; Heidrun Behrendt; Stephen R Durham; Carsten B Schmidt-Weber; Andrea Cavani
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

10.  Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10.

Authors:  Diane Lejeune; Laure Dumoutier; Stefan Constantinescu; Wiebe Kruijer; Jan Jacob Schuringa; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2002-06-26       Impact factor: 5.157

View more
  25 in total

1.  Immune responses of dendritic cells combined with tumor-derived autophagosome vaccine on hepatocellular carcinoma.

Authors:  Yongxiang Yi; Jianbo Han; Liang Zhao; Chunying Wang; Yuan Fang; Qiang Wei; Liang Hu; Junmao Liu; Yufeng Zhang; Lili Wang
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

2.  Activation of Toll-like receptors signaling in non-small cell lung cancer cell line induced by tumor-associated macrophages.

Authors:  Xing Ke; Meng Wu; Jianfang Lou; Shuping Zhang; Peijun Huang; Ruihong Sun; Lei Huang; Erfu Xie; Fang Wang; Bing Gu
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 3.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

Review 4.  T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.

Authors:  Jin Bian; Jianzhen Lin; Junyu Long; Xu Yang; Xiaobo Yang; Xin Lu; Xinting Sang; Haitao Zhao
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 5.  Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma.

Authors:  Alexis L Santana; Diane Felsen; John A Carucci
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

6.  Th22 cell accumulation is associated with colorectal cancer development.

Authors:  Yong-Hong Huang; Yun-Fei Cao; Zhi-Yuan Jiang; Sen Zhang; Feng Gao
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 7.  Mechanisms of liver fibrosis and its role in liver cancer.

Authors:  Debanjan Dhar; Jacopo Baglieri; Tatiana Kisseleva; David A Brenner
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-10

8.  Association of interleukin 22 polymorphisms with gastric cancer risk.

Authors:  Shan-yu Qin; Xian-wen Yang; Wei Luo; Mei Chen; Zhi-ling Liu; Si-biao Su; Hai-xing Jiang
Journal:  Tumour Biol       Date:  2014-11-12

9.  Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.

Authors:  Melody Abikhair; Hiroshi Mitsui; Valerie Yanofsky; Nazanin Roudiani; Channa Ovits; Teddy Bryan; Tatiana M Oberyszyn; Kathleen L Tober; Juana Gonzalez; James G Krueger; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2016-06-02

Review 10.  Immunology of hepatocellular carcinoma.

Authors:  Meenakshi Sachdeva; Yogesh K Chawla; Sunil K Arora
Journal:  World J Hepatol       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.